Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide + AZD5363 in metastatic castration-resistant prostate cancer
ISRCTN17168679Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Dec 2014
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of enzalutamide and capivasertib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Royal Marsden NHS Foundation Trust. Started Dec 2014; status: completed.
02
Drugs
enzalutamidecapivasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ISRCTN17168679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17168679.